{"schema":"rootz.ai/sec-company/v1","layer":1,"cik":"0001159036","name":"HALOZYME THERAPEUTICS, INC.","summary":"Halozyme Therapeutics is a biopharmaceutical company that licenses its ENHANZE drug delivery technology (based on proprietary enzyme rHuPH20) to enable subcutaneous delivery of injectable biologics and small molecules. It earns royalties from ten approved partner products, markets proprietary products Hylenex and XYOSTED, and develops auto-injector devices. Recent acquisitions expanded its portfolio with Hypercon and Surf Bio hyperconcentration technologies.","people":[],"products":[{"name":"ENHANZE","type":"platform","description":"Drug delivery technology using rHuPH20 enzyme to facilitate subcutaneous delivery of high-volume injectable biologics and small molecules."},{"name":"Hypercon technology","type":"platform","description":"Microparticle technology enabling hyperconcentration of monoclonal antibodies and biologics up to ~500 mg/mL for SC delivery."},{"name":"Surf Bio technology","type":"platform","description":"Polymer-enabled hyperconcentration technology enabling SC concentrations up to 500 mg/mL for biologics and small molecules."},{"name":"Hylenex Recombinant","type":"hardware","description":"FDA-approved rHuPH20 formulation for facilitating SC fluid administration, drug absorption, and SC urography; number one prescribed branded hyaluronidase."},{"name":"XYOSTED","type":"hardware","description":"FDA-approved SC testosterone enanthate injection for once-weekly at-home self-administration in adult males with testosterone deficiency."},{"name":"VIBEX","type":"hardware","description":"Pressure-assisted auto-injector device for SC or intramuscular drug delivery."},{"name":"VIBEX QuickShot","type":"hardware","description":"Pressure-assisted auto-injector platform designed for speed and patient comfort with customizable fill volumes."},{"name":"Vai auto-injector","type":"hardware","description":"Auto-injector device platform accommodating highly viscous drug products with dose capacity from 0.5 mL to 2.25 mL."},{"name":"High-volume auto-injector","type":"hardware","description":"Auto-injector extending dose capacity to at least 10 mL, utilizing ENHANZE technology; Phase I study completed in 2023."}],"partnerships":[{"partner_name":"F. Hoffmann-La Roche / Hoffmann-La Roche (Roche)","partnership_type":"licensing","description":"ENHANZE collaboration since 2006; Roche licensed up to twelve targets; five commercial products including Herceptin SC, Herceptin Hylecta, and Phesgo.","start_date":null},{"partner_name":"Takeda Pharmaceuticals / Baxalta","partnership_type":"licensing","description":"ENHANZE collaboration; one commercial product generating royalties for Halozyme.","start_date":null},{"partner_name":"Pfizer Inc.","partnership_type":"licensing","description":"ENHANZE collaboration and licensing agreement for subcutaneous drug delivery applications.","start_date":null},{"partner_name":"Janssen Biotech, Inc.","partnership_type":"licensing","description":"ENHANZE collaboration with two commercial products; also has Hypercon collaboration and license agreement.","start_date":null},{"partner_name":"AbbVie, Inc.","partnership_type":"licensing","description":"ENHANZE collaboration and licensing agreement for SC drug delivery.","start_date":null},{"partner_name":"Eli Lilly and Company","partnership_type":"licensing","description":"ENHANZE collaboration and licensing agreement; also has Hypercon collaboration and license agreement.","start_date":null},{"partner_name":"Bristol-Myers Squibb Company (BMS)","partnership_type":"licensing","description":"ENHANZE collaboration with one commercial product generating royalties.","start_date":null},{"partner_name":"argenx BVBA","partnership_type":"licensing","description":"ENHANZE collaboration with one commercial product; also has Hypercon collaboration and license agreement.","start_date":null},{"partner_name":"ViiV Healthcare","partnership_type":"licensing","description":"ENHANZE collaboration; ViiV is the global specialist HIV company majority owned by GlaxoSmithKline.","start_date":null},{"partner_name":"Chugai Pharmaceutical Co., Ltd.","partnership_type":"licensing","description":"ENHANZE collaboration; Chugai is a member of the Roche Group and obtained Phesgo approval in Japan in September 2023.","start_date":null},{"partner_name":"Acumen Pharmaceuticals, Inc.","partnership_type":"licensing","description":"ENHANZE collaboration and licensing agreement.","start_date":null},{"partner_name":"Merus N.V.","partnership_type":"licensing","description":"ENHANZE collaboration and licensing agreement.","start_date":null},{"partner_name":"Skye Bioscience, Inc.","partnership_type":"licensing","description":"ENHANZE collaboration and licensing agreement.","start_date":null},{"partner_name":"Teva Pharmaceutical Industries, Ltd.","partnership_type":"OEM","description":"Commercialized auto-injector products with Halozyme.","start_date":null},{"partner_name":"McDermott Laboratories Limited (affiliate of Viatris Inc.)","partnership_type":"development","description":"Auto-injector development programs underway.","start_date":null}],"affiliations":[],"origin":{"leaf":"f1b78ad220975f97a285881692e637064f6669fcd7ff18880fd1256c5235cad8","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"7eee59ac0be0875e6dab5d4e74d884aef00e58a11c16d35a00643937f40d22c2","parent":"9749651b8d1bbfd9fdfbdef7cdce1e6220764fe9af97845522d4a479d20b6a51","source":"0001159036-26-000024","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":14,"hourly_limit":500,"remaining":486,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}